NexImmune competitors

Zippia score 4.1

Competitor Summary. See how NexImmune compares to its main competitors:

Fate Therapeutics has the most employees (104).
The oldest company is BioTime, founded in 1990.

Work at NexImmune?

Share your experience

NexImmune vs competitors

Company	Founding date	Zippia score	Headquarters	# of Locations	Revenue	Employees
NexImmune	2011	4.1	Gaithersburg, MD	1	$31.0M	1,942
Fate Therapeutics	2007	4.5	San Diego, CA	1	$13.6M	104
BioTime	1990	3.4	Alameda, CA	1	$3.4M	101
Onconova Therapeutics	1998	3.4	Newtown, PA	3	$226,000	12
Trillium Therapeutics	2004	4.0	-	1	$148,000	20
INmune Bio	2015	3.7	San Diego, CA	1	$14,000	5
Immune Therapeutics	2012	3.5	Orlando, FL	1	$113,500	2
Cue Biopharma	2014	4.0	Cambridge, MA	1	$9.3M	46
Genocea	2006	3.7	Cambridge, MA	1	-	59

Rate NexImmune's competitiveness in the market.

NexImmune salaries vs competitors

Compare NexImmune salaries vs competitors

Company	Average salary	Hourly salary	Salary score
NexImmune	$56,251	$27.04	-

Compare NexImmune job title salaries vs competitors

Company	Highest salary	Hourly salary
NexImmune	$36,938	$17.76
Genocea	$40,048	$19.25
Fate Therapeutics	$39,394	$18.94
Onconova Therapeutics	$39,148	$18.82
BioTime	$35,226	$16.94
Trillium Therapeutics	$33,549	$16.13
Immune Therapeutics	$33,200	$15.96
INmune Bio	$30,841	$14.83
Cue Biopharma	$30,744	$14.78

Do you work at NexImmune?

Does NexImmune effectively differentiate itself from competitors?

NexImmune jobs

NexImmune demographics vs competitors

Compare gender at NexImmune vs competitors

Job title	Male	Female
Onconova Therapeutics	63%	38%
NexImmune	-	-

Male

Female

100%

75%

50%

25%

NexImmune

Onconova Therapeutics

25%

50%

75%

100%

Compare race at NexImmune vs competitors

Company	White	Hispanic or Latino	Black or African American	Asian	Unknown	Diversity score
Onconova Therapeutics	49%	12%	12%	26%	1%	6.6

NexImmune and similar companies CEOs

CEOBio

Brian Culley

BioTime

Experienced public company CEO determined to leave the world a healthier place than when he arrived by developing new treatments for serious diseases and conditions.

J. Scott Wolchko

Fate Therapeutics

J Scott Wolchko are a President/CEO/COO at FATE THERAPEUTICS INC and Board Member at FATE THERAPEUTICS INC. They have worked as Chief Financial Officer at Bocada and VP:Operations/CFO at FATE THERAPEUTICS INC. J studied at University of Virginia and Alpha Omega Alpha Medical Honor Society.

Chip Clark

Genocea

Prior to joining Genocea,Chip co-founded and served as Chief Business Officer of Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Before that, Chip was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial roles at SmithKline Beecham (now GlaxoSmithKline). Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

Raymond J. Tesi

INmune Bio

Raymond Tesi is a Chair/Pres/CEO/Acting Chief Medical Ofcr at INmune Bio Inc., Chairman at INmune Bio Inc., and Board Member at Savant HWP. He has worked as CEO/President/Founder at Coronado Biosciences, Senior VP at SANGSTAT MEDICAL CORP, and Associate Professor at Tulane University School of Medicine. Raymond works or has worked as FELLOW at American College of Surgery. He attended Washington University in St LO and WASHINGTON UNIVERSITY.

Jan Skvarka

Trillium Therapeutics

Jan Skvarka is a Board Member at TRILLIUM THERAPEUTICS INC and President/CEO at TRILLIUM THERAPEUTICS INC and is based in Cambridge, Massachusetts. He has worked as President/CEO at Tal Medical Inc, Partner at Bain & Company, and Manager at Pricewaterhouse Coopers (PwC). Jan attended Harvard Business School between 1998 and 1999 and University of Economics, Bratislava, Slovakia.